Precision Treatment With Angiotensin Converting Enzyme Inhibitor

• Status: Completed
• Trial end date: 2021-08-02
• Target enrollment: 0
• Participant gender: All

Summary

Angiotensin converting enzyme inhibitors (ACEI) are the first-line treatment for high blood pressure and congestive heart failure, and have excellent effects in improving the prognosis of cardiovascular diseases. However, ACEI is frequently discontinued due to its adverse reaction. The adverse reaction to ACEI is not uncommon, especially in Asians. Discontinuation of ACEI is known to increase the risk of poor prognosis of cardiovascular diseases.

Biomarkers for predicting adverse reaction to ACEI have not yet been developed. Recently, genes related to adverse reaction to ACEI have been identified. This study is a randomized prospective study, in which the experimental group decides whether to administer the drug based on genetic information, and the control group decides whether to administer the drug without the information. In the experimental group, participants who are predicted to have a high risk of adverse reation to ACEI will receive angiotensin receptor blockers (ARB), and those who are predicted to have a low risk of adverse reaction will receive ACEI. Control group will receive ACEI. The frequency of adverse reaction will be investigated between control and experimental groups. In the genotyping and control groups, at least 45 and 31 will be enrolled, respectively, and after drug administration, a phone follow-up will be conducted at 3 weeks, followed by a visit at the 6th week, and the study will be terminated.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yonsei University
• Treatments: Perindopril

Criteria

Inclusion Criteria:

• Men and women over 20 years of age and less than 80 years of age

• Patients taking ACEI due to hypertension or heart failure

• Patients who voluntarily decided to participate after hearing the clinical study explanation

Exclusion Criteria:

• Patients who refused to participate in the study

• Patients with a history of adverse reactions to ACEI

• Patients with contraindications to the use of ACEI

• Patients who participated in other clinical trials within 30 days of screening